Septic abscess in a child with juvenile idiopathic arthritis receiving anti-tumor necrosis factor-α therapy [1]

Journal of Rheumatology

Volumn 33, Issue 4, 2006, Pages 825-

  Fitch, Pamela G ^a   Cron, Randy Q ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CLINDAMYCIN; COTRIMOXAZOLE; ETANERCEPT; INFLIXIMAB; METHOTREXATE; NAPROXEN; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VANCOMYCIN;

ABSCESS; ACTINOBACILLUS; ACTINOBACILLUS UREA; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIAL ARTHRITIS; BACTERIUM CULTURE; CASE REPORT; FEMALE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LETTER; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NECROTIZING FASCIITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SCHOOL CHILD; SEPTIC ABSCESS;

ABSCESS; ANTI-BACTERIAL AGENTS; ARTHRITIS, INFECTIOUS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; RECEPTORS, TUMOR NECROSIS FACTOR; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33645834545     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (11)

1. Kaur PP, Derk CT, Chatterji M, Dehoratius RJ. Septic arthritis caused by Actinobacillus ureae in a patient with rheumatoid arthritis receiving anti-tumor necrosis factor-α therapy. J Rheumatol 2004;31:1663-5.
2. Siegel JN. Clinical review for Enbrel (etanercept). Available from: www.fda.gov/CDER/biologics/review/etanimm110298r2.pdf. Accessed February 1, 2006.
3. Phillips K, Husni ME, Karlson EW, Coblyn JS. Experience with etanercept in an academic medical center: are infection rates increased? Arthritis Rheum 2002;47:17-21.
4. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
5. Baeten D, Kruithof E, van den Bosch F, et al. Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis 2003;62:829-34.
6. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 2001;96:722-9.
7. Etanercept (Enbrel) package insert. Thousand Oaks, CA: Immunex Corp.; 2003.
8. Lovell DJ, Giannini EH, Reiff A, et al. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum 2003; 48:218-26.
9. Lovell D, Reiff A, Jones OY, et al. Long-term safety and efficacy experience with etanercept (Enbrel) in children with polyarticular juvenile rheumatoid arthritis [abstract]. Arthritis Rheum 2004;50 Suppl:S436.
10. Cron RQ. Current treatment for chronic arthritis in childhood. Curr Opin Pediatr 2002;14:684-7.
11. Song XY, Fox F, Gallo MA, et al. Effects of 2 different anti-tumor necrosis factor-α agents in a primate model of subcutaneous abscess formation. J Infect Dis 2002;185:204-13.